Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations
Dominik Rottenkolber(Helmholtz Zentrum München), Joerg Hasford(Ludwig-Maximilians-Universität München), Silke Mueller(University of Rostock), Katrin Farker(Jena University Hospital), Marietta Rottenkolber(Zimmer Biomet (Germany)), Marion Hippius, Karen Saljé(Universität Greifswald), Petra Thuermann(Helios Universitätsklinikum Wuppertal), Sven Schmiedl(Witten/Herdecke University)
Cited by 169
Related Papers
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort
|The Lancet Diabetes & Endocrinology|2017|951
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573